Work

Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.

Year: 2022

Type: article

Abstract: notably reduced tumor burden, which was accompanied by decreased microvessel density and concurrent induction of the luminal epithelial marker E-cadherin. Thus, CNN1/CYR61-targeting strategies might have therapeutic value in suppressing the biological aggressiveness of triple-negative/basal-like BC.

Source: PubMed Central

Authors: Ingrid Espinoza, Chandra Kurapaty, Cheol-Hong Park, Travis Vander Steen, Celina G Kleer, Elizabeth Wiley, Alfred Rademaker, Elisabet Cuyàs, Sara Verdura, Maria Buxó, Carol Reynolds, Javier A Menendez, Ruth Lupu

Institutions: Mayo Clinic, University of Mississippi Medical Center, University of Michigan, University of Illinois Chicago, Northwestern University, Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Girona, Mayo Clinic Comprehensive Cancer Center (Minnesota)

Language: English

Topic: Connective Tissue Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: Cyr61-induced breast cancer: Clinical relevance and therapeutic development, Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention, Role of CCN6 (WISP3) in the progression and metastasis of breast cancer

OpenAlex ID: W4226139743

FWCI: 1.306

Cites: 48

Cited by: 16

Related to: 10